First Distributor signed for Remplir in $75m Canadian Market
Filed with ASX · · 3 pages · English
Story so far
Earlier from Orthocell
- Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery
- Remplir Use in Prostate Surgery Signals Global Opportunity
- Remplir™ Study Delivers Compelling 81% Success Rate
- Compelling 81% Success Rate for Remplir
- Appendix 4E & Annual Report
Later from Orthocell
- Another Record Revenue Quarter for Orthocell
- Trading Halt
- $30m Placement Sees Orthocell Positioned for Rapid Growth
- OCC Secures Rights to High-Value Bone Regeneration Tech
- HK Distributor Signed as Remplir Expands in the Asian Market
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell